International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials.
about
Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of diseaseA retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis.Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.Juvenile dermatomyositis: new insights and new treatment strategies.Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study.Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositisThe juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomesMorphometric analyses of normal pediatric brachial biceps and quadriceps muscle tissue.Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.The Correlation of Muscle Biopsy Scores with the Clinical Variables in Idiopathic Inflammatory Myopathies.Consensus-based recommendations for the management of juvenile dermatomyositis.Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositisClinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.IFN-β-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis.Integrated classification of inflammatory myopathies.HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap.Dermatomyositis: factors predicting relapse.Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis.Limb girdle muscular dystrophy type 2B masquerading as inflammatory myopathy: case report.Efficacy of ultrasound elastography in detecting active myositis in children: can it replace MRI?A semiquantitative scoring tool to evaluate eccentric exercise-induced muscle damage in trained rats.The lymphoid follicle variant of dermatomyositis.Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis.Higher proportion of fast-twitch (type II) muscle fibres in idiopathic inflammatory myopathies - evident in chronic but not in untreated newly diagnosed patients.Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis.Useful pharmacodynamic endpoints in children: selection, measurement, and next steps.CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α.The Vasculopathy of Juvenile Dermatomyositis
P2860
Q28652726-6B0765D7-21A4-4E12-83DB-F8B0BDF419C8Q33569443-6C6E78E5-E468-4933-811C-47F6D9AADF87Q34486301-103902AB-0FA1-4204-9151-514DC4696959Q35009335-5F759CE6-CA70-417A-B515-69849DC70569Q36059542-8B97D638-AC57-44B7-9310-0CEDA44C15AEQ36335887-FB15D79A-2A77-4507-857A-178AF33CF7F3Q36498667-EB283848-A1DA-4AD7-8596-B0815C40E148Q36842564-777065A4-7B4C-43CB-A3A5-A4A38822D616Q37022721-EA18AF60-A72B-4D38-B6E5-43FAE2F9C78DQ37087734-7FC8C5DD-7165-44A7-9572-4C90531D2EA5Q37388175-BB529415-5B0F-4525-9805-A0002A9A87F6Q37570702-75091C69-36DE-41C4-BC8B-D6AAC24F7AF9Q37617000-792D8135-2AE5-4698-873B-E23C76C25137Q37689900-8C8FE509-131D-4488-8882-54FC9EA7F83EQ37938701-88FE2278-31C9-4C32-ACFA-900F3362A1F0Q38721602-A45B7902-EB68-4796-B083-46C09F11F163Q39027323-4A007AFF-208E-400C-95AD-5FDC943B44EAQ40154248-0F401AE7-4DA3-4E77-823C-EA2F05CB4146Q40209605-704EC7CD-D93D-4519-8127-CD42313BE2D7Q40479791-71B5EA1C-49C9-4D5C-A616-C9ADCA07F8FAQ40663721-24551601-6C2B-4610-9C8E-F326A535AAB7Q41026824-9DF1E39C-A648-4111-AFED-F2866C66D68FQ41356527-7B8CA4B1-B77C-4C15-8AC6-F6F3B53E02B6Q41690884-E5AB6266-6162-4F63-A8CF-F514EEA679D8Q52864090-0900A8CF-9CA7-4536-A882-960290BFF689Q54637626-AF2EF1D9-F19B-4619-BAAB-F411A3E98420Q55040612-9D603EEC-DA96-431C-8635-39C5B05F6861Q55360869-EB76E88A-2B0C-4A0F-A371-AE5C79445120Q55487166-85538EA3-6854-4DED-A744-AB8F4194C6D7Q57816912-E0E0110A-908B-4F30-BCE1-E833AE16D6C5
P2860
International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
International consensus on a p ...... ential use in clinical trials.
@en
type
label
International consensus on a p ...... ential use in clinical trials.
@en
prefLabel
International consensus on a p ...... ential use in clinical trials.
@en
P2093
P2860
P50
P356
P1476
International consensus on a p ...... tential use in clinical trials
@en
P2093
Alison Emslie-Smith
Andrea M Corse
Anthony A Amato
Brenda Banwell
Brian Harding
Carlo Minetti
Caroline Sewry
Charles K C Li
Clarissa A Pilkington
Elisabeth J Rushing
P2860
P304
P356
10.1002/ART.23012
P577
2007-10-01T00:00:00Z